All In Biotech

NDA 020066 · Haleon US Holdings

Nicorette

Nicotine Polacrilex · Buccal · Cholinergic Nicotinic Agonist

Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Jun 8, 1992

Approved uses

4

Original approval plus efficacy supplements

Registered trials

873

97 Phase 3, 66 recruiting

FAERS reports

36,363

14,086 serious, 1,717 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 30, 2024.

Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 6, 2009 Supplement 33 · Efficacy Letter
  • Dec 23, 1998 Supplement 7 · Efficacy ReviewLetterLabel
  • Feb 9, 1996 Supplement 4 · Efficacy
  • Jun 8, 1992 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • NICORETTE · NICOTINE POLACRILEX EQ 4MG BASE · GUM, CHEWING, BUCCAL · Over-the-counter
  • NICORETTE · NICOTINE POLACRILEX EQ 4MG BASE · GUM, CHEWING, BUCCAL · Over-the-counter
  • NICORETTE (MINT) · NICOTINE POLACRILEX EQ 4MG BASE · GUM, CHEWING, BUCCAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicotine Polacrilex" as an intervention, any sponsor and status, largest first.

All 873 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,769
  • nicotine dependence4,064
  • intentional drug misuse3,435
  • nausea2,816
  • malaise1,480
  • headache1,255
  • dizziness1,244
  • drug administration error1,176
  • overdose1,129
  • vomiting1,050
  • product quality issue1,038
  • wrong technique in product usage process956

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004327
2005411
20061,437
20071,747
20081,352
20091,495
20101,492
20111,955
20122,045
20131,575
2014722
20152,088
20162,005
20171,902
20183,011
20192,150
20201,968
20211,800
20221,512
20231,469
20241,433
20251,504
2026963

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 77 on PubMed

Sponsor: Haleon US Holdings · Also marketed as Nicorette (Mint)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.